Clinical Trials Browser

paclitaxel-Angiopep-2 conjugate × CNS × Clear all

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT01967810 2020-02-25

ANG1005 in Patients With Recurrent High-Grade Glioma

Phase 2 Completed

73 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma, Recurrence

NCT02048059 2020-02-25

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Phase 2 Completed

72 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01497665 2019-01-22

GRABM-L

Phase 2 Terminated

16 enrolled 7 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01480583 2016-07-13

GRABM-B

Phase 2 Completed

85 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02755987 2016-06-07

Expanded Access to ANG1005 for Individual Patients

No longer available

CNS

Astrocytoma, Oligodendroglioma, Meningeal Carcinomatosis

NCT00539344 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Phase 1 Completed

63 enrolled

CNS

Astrocytoma, Glioblastoma, Oligodendroglioma, Recurrence

NCT00539383 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

Phase 1 Completed

56 enrolled

BreastCNSDermatologicGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma

Clinical Trials

ANGLeD

ANG1005 in Patients With Recurrent High-Grade Glioma

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

GRABM-L

GRABM-B

Expanded Access to ANG1005 for Individual Patients

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer